基于转化生长因子β/Smad信号通路探讨中医药干预上皮-间质转化的研究进展  

Research Progress of TCM Intervention on Epithelial-Mesenchymal Transition Based on Transforming Growth Factor-β/Smad Signaling Pathway

作　　者：李凯欣 刘朴霖 阎小燕[2] LI Kaixin;LIU Pulin;YAN Xiaoyan(Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Geriatrics Department,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China)

机构地区：[1]山东中医药大学,山东省济南市250014 [2]山东中医药大学附属医院老年医学科,山东省济南市250014

出　　处：《实用心脑肺血管病杂志》2022年第12期70-74,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：山东省自然科学基金资助项目(ZR2021MF118);泰山学者建设工程专项经费资助项目(ts201712096);山东省中医药管理局资助项目(2020Z06)。

摘　　要：肺纤维化是一种慢性进行性间质性肺疾病,病因不明,预后较差。西医治疗有吡非尼酮、尼达尼布、氧疗、肺移植等方式,但上述治疗方式费用昂贵,极大地增加了患者的经济负担,已有研究证明中医药治疗肺纤维化具有独特优势。上皮-间质转化(EMT)是肺纤维化发生发展的重要环节,本文总结了基于转化生长因子β(TGF-β)/Smad信号通路中医药干预EMT进而缓解肺纤维化的研究,以期为肺纤维化的研究提供方向。Pulmonary fibrosis is a chronic progressive interstitial lung disease with unknown etiology and poor prognosis.Western medicine treatment includes pirfenidone,nidanib,oxygen therapy,lung transplantation and other methods,but the treatment costs are expensive and greatly increase the economic pressure of patients.Studies have proved that traditional Chinese medicine has unique advantages in the treatment of pulmonary fibrosis.Epithelial-mesenchymal transformation(EMT)is an important link in the occurrence and development of pulmonary fibrosis.In this paper summarizes the research on TCM intervention on EMT based on transforming growth factor-β(TGF-β)/Smad signaling pathway to alleviate pulmonary fibrosis,in order to provide a direction for the study of pulmonary fibrosis.

关 键 词：肺纤维化 中医药 上皮-间质转化 转化生长因子Β 转化生长因子β/Smad信号通路 综述 

分 类 号：R563.13[医药卫生—呼吸系统]